title: DNA intercalation and inhibition of topoisomerase II. Structure-activity relationships for a series of amiloride analogs.
abstract: Among its many properties, amiloride is a DNA intercalator and topoisomerase II inhibitor. Previous work has indicated that the most stable conformation for amiloride is a planar, hydrogen-bonded, tricyclic structure. To determine whether the ability of amiloride to intercalate into DNA and to inhibit DNA topoisomerase II was dependent on the ability to assume a cyclized conformation, we studied the structure-activity relationship for 12 amiloride analogs. These analogs contained structural modifications which could be expected to allow or impede formation of a cyclized conformation. Empirical assays consisting of biophysical, biochemical, and cell biological approaches, as well as computational molecular modeling approaches, were used to determine conformational properties for these molecules, and to determine whether they intercalated into DNA and inhibited topoisomerase II. Specifically, we measured the ability of these compounds to 1) alter the thermal denaturation profile of DNA, 2) modify the hydrodynamic behavior of DNA, 3) inhibit the catalytic activity of purified DNA topoisomerase II in vitro, 4) promote the topoisomerase II-dependent cleavage of DNA, and 5) inhibit functions associated with DNA topoisomerase II in intact cells. Results indicated that only those analogs capable of cyclization could intercalate into DNA and inhibit topoisomerase II. Thus, the ability of amiloride and the 12 analogs studied to intercalate into DNA and to inhibit topoisomerase II appears dependent on the ability to exist in a planar, hydrogen-bonded, tricyclic conformation.
authors.affiliation: Department of Molecular Biology, Wellcome Research Laboratories, Research Triangle Park, North Carolina 27709.
authors.forename: J M
authors.initials: JM
authors.lastname: Besterman
authors.forename: L P
authors.initials: LP
authors.lastname: Elwell
authors.forename: E J
authors.initials: EJ
authors.lastname: Cragoe
authors.forename: C W
authors.initials: CW
authors.lastname: Andrews
authors.forename: M
authors.initials: M
authors.lastname: Cory
mesh_terms: D000584:Amiloride / Q000031:analogs & derivatives* / Q000494:pharmacology*; D000818:Animals; D002417:Cattle; D004247:DNA / Q000187:drug effects / Q000378:metabolism*; D007364:Intercalating Agents; D008958:Models, Molecular; D008968:Molecular Conformation; D009690:Nucleic Acid Conformation; D009838:Oligodeoxyribonucleotides; D013329:Structure-Activity Relationship; D013950:Thymus Gland / Q000201:enzymology; D059005:Topoisomerase II Inhibitors
chemical_list: D007364:Intercalating Agents; D009838:Oligodeoxyribonucleotides; D059005:Topoisomerase II Inhibitors; D000584:Amiloride; D004247:DNA